Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Summary by MarketBeat
Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday.

1 Articles

MarketBeatMarketBeat
Center

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Friday, July 31, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Tarrytown icon

Tarrytown

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal